Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$2.12 - $4.18 $13,629 - $26,873
6,429 Added 0.81%
795,549 $3.22 Million
Q3 2023

Nov 14, 2023

BUY
$2.66 - $10.04 $153,468 - $579,257
57,695 Added 7.89%
789,120 $2.12 Million
Q2 2023

Aug 14, 2023

BUY
$7.28 - $11.82 $221,777 - $360,084
30,464 Added 4.35%
731,425 $6.82 Million
Q1 2023

May 15, 2023

BUY
$5.21 - $14.05 $325,567 - $877,970
62,489 Added 9.79%
700,961 $6.22 Million
Q4 2022

Feb 10, 2023

BUY
$4.69 - $8.36 $58,761 - $104,742
12,529 Added 2.0%
638,472 $3.18 Million
Q3 2022

Nov 14, 2022

SELL
$5.7 - $8.68 $19,214 - $29,260
-3,371 Reduced 0.54%
625,943 $3.63 Million
Q2 2022

Aug 12, 2022

BUY
$5.04 - $14.05 $720,478 - $2.01 Million
142,952 Added 29.39%
629,314 $3.48 Million
Q1 2022

May 13, 2022

SELL
$8.75 - $14.51 $3,465 - $5,745
-396 Reduced 0.08%
486,362 $5.61 Million
Q4 2021

Feb 14, 2022

BUY
$8.98 - $20.09 $4.37 Million - $9.78 Million
486,758 New
486,758 $6.17 Million

Others Institutions Holding THRX

About Theseus Pharmaceuticals, Inc.


  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.